Faulty List At SAIHST, we have faculties from various backgrounds such as ; basic science, clinical medicine, pharmacology, engineering, business etc. SAIHST is always open for future competent faculties to lead biomedical science.
| Hye Ryoun Jang / M.D., Ph.D. |
Name : Hye Ryoun Jang M.D., Ph.D.
Department : Medical
Title : Professor
Campus : Samsung medical center campus
Office : Future Hall of Medicine, Samsung Medical Center B3 Lab #2
E-mail : shinehr@skku.edu, hyeryoun.jang@samsung.com
Homepage : 추후 개설 예정
Lab. title : Kidney disease and iPSCs lab.
Related Department : Department of Health Sciences and Technology
Print
|
|
■ Career
1994-2000 Seoul National University College of Medicine 2000-2001 Seoul National University Hospital, intern 2001-2005 Seoul National University Hospital, resident (Internal Medicine) 2002-2004 Seoul National University Master: Medicine (renal physiology) 2005-2007 Seoul National University Ph.D.: Medicine (renal physiology) 2005-2007 Seoul National University Hospital, fellow (nephrology) 2007-2009 Johns Hopkins University, postdoctoral fellow (nephrology) 2010-2011 Sungkyunkwan University School of Medicine, Samsung Medical Center, Nephrology, clinical assistant professor 2011-2015 Sungkyunkwan University School of Medicine, Samsung Medical Center, Nephrology, assistant professor 2015-2021 Sungkyunkwan University School of Medicine, Samsung Medical Center, Nephrology, associate professor 2015-2016 Stanford University Cardiovascular Institute, visiting scholar 2021-present Sungkyunkwan University School of Medicine, Samsung Medical Center, Nephrology, professor ■ Research interests -Research area: Ischemic acute kidney injury / Investigation of cardiovascular disease using chronic kidney disease patient-specific induced pluripotent stem cells -Laboratory name: Kidney disease and iPSCs lab. -Homepage: will be available ■ Research Introduction Our lab has been investigating the cardiovascular complications of chronic kidney disease using patient-specific induced pluripotent stem cells (iPSCs) and ischemic acute kidney injury. We have been performing various experiments regarding immunologic mechanisms and disease susceptibility of ischemic acute kidney injury with both murine renal ischemia-reperfusion injury models and hypoxic injury models of tubular cells. We have also conducted translational research using patient blood and urine samples to identify clinically reliable biomarkers for elucidating underlying mechanisms and developing tools of early diagnosis and novel drug screening. To develop a novel research technique and screen drugs for cardiovascular diseases, the most serious complication of chronic kidney disease, we are conducting various experiments using endothelial cells differentiated from patient-specific iPSCs. ■ Keywords: ischemic acute kidney injury, patient-specific iPSCs, cardiovascular complications of chronic kidney disease ■ Selected Publications 1. Calpain Inhibition Restores Autophagy and Prevents Mitochondrial Fragmentation in a Human iPSC Model of Diabetic Endotheliopathy. Stem Cell Reports. 2019 Mar 5;12(3):597-610. 2. Poly (ADP-Ribose) Polymerase Inhibitor Treatment as a Novel Therapy Attenuating Renal Ischemia-Reperfusion Injury. Front Immunol. 2020 Oct 14;11:564288. 3. Modeling Uremic Vasculopathy With Induced Pluripotent Stem Cell-Derived Endothelial Cells as a Drug Screening System. Front Cell Dev Biol. 2021 Jan 12;8:618796. 4. Dietary Modification Alters the Intrarenal Immunologic Micromilieu and Susceptibility to Ischemic Acute Kidney Injury. Front Immunol. 2021 Mar 11;12:621176. 5. Effects of poly (ADP-ribose) polymerase inhibitor treatment on the repair process of ischemic acute kidney injury. Sci Rep. 2024 Jan 2;14(1):159. Additional 40 papers |